Javascript must be enabled to continue!
Optimizing mHealth Instant Messaging-Based Smoking Cessation Support: A Sequential, Multiple Assignment, Randomized Trial (SMART)
View through CrossRef
AbstractMobile health (mHealth) messaging has been used to enhance quitting. Optimal sequencing of more personalized and intensive interventions may increase abstinence for mHealth non-responders (continuing smokers). We aim to test the effectiveness and cost of an adaptive design intervention based on chat-based personalized instant messaging (PIM) versus that based on regular instant messaging (RIM; non-personalized) on validated abstinence. Sequential, multiple assignment randomized trial proactively recruited adult daily cigarette smokers in Hong Kong. At baseline, participants received brief cessation advice plus referral assistance to cessation services and were randomized to receive PIM (PIM group, n = 422) or RIM (RIM group, n = 422). At 1 month, PIM non-responders were further randomized (ratio 3:1) to receive either combined cessation interventions (CCI, including multi-media messages, nicotine replacement therapy sampling, incentive for service referral, phone counselling, family/peer group chat) or maintained PIM for 2 months. RIM non-responders were further randomized (ratio 1:3) to receive PIM or maintained RIM. Responders (quitters) in either group continued to receive the respective initial intervention. Bio-validated abstinence at 6 months by intention-to-treat. The 844 participants were mostly male (82.3%). At 1 month, 370 (87.7%) and 373 (88.4%) non-responded to PIM and RIM, respectively. Of non-responders, 273 (73.8%) received CCI and 91 (24.4%) received PIM. At 6 months, PIM group had non-significantly higher validated abstinence than RIM group (10.2% vs. 8.3%, risk ratio [RR] 1.23, 95%CI 0.80 to 1.88) at doubled cost (US$33,228.8 vs. 15,985.5). In non-responders, receiving CCI (vs. maintained PIM: 4.8% vs. 6.2%, RR 0.77, 95%CI 0.30 to 1.97) or PIM (vs. maintained RIM: 3.3% vs 5.7%, RR 0.58, 95%CI 0.17 to 1.95) did not increase validated abstinence. The PIM-based adaptive intervention did not significantly increase validated abstinence than that of non-personalized IM. Non-responders to PIM or RIM did not benefit from more intensive interventions. ClinicalTrials.gov Identifier: NCT03992742
Springer Science and Business Media LLC
Title: Optimizing mHealth Instant Messaging-Based Smoking Cessation Support: A Sequential, Multiple Assignment, Randomized Trial (SMART)
Description:
AbstractMobile health (mHealth) messaging has been used to enhance quitting.
Optimal sequencing of more personalized and intensive interventions may increase abstinence for mHealth non-responders (continuing smokers).
We aim to test the effectiveness and cost of an adaptive design intervention based on chat-based personalized instant messaging (PIM) versus that based on regular instant messaging (RIM; non-personalized) on validated abstinence.
Sequential, multiple assignment randomized trial proactively recruited adult daily cigarette smokers in Hong Kong.
At baseline, participants received brief cessation advice plus referral assistance to cessation services and were randomized to receive PIM (PIM group, n = 422) or RIM (RIM group, n = 422).
At 1 month, PIM non-responders were further randomized (ratio 3:1) to receive either combined cessation interventions (CCI, including multi-media messages, nicotine replacement therapy sampling, incentive for service referral, phone counselling, family/peer group chat) or maintained PIM for 2 months.
RIM non-responders were further randomized (ratio 1:3) to receive PIM or maintained RIM.
Responders (quitters) in either group continued to receive the respective initial intervention.
Bio-validated abstinence at 6 months by intention-to-treat.
The 844 participants were mostly male (82.
3%).
At 1 month, 370 (87.
7%) and 373 (88.
4%) non-responded to PIM and RIM, respectively.
Of non-responders, 273 (73.
8%) received CCI and 91 (24.
4%) received PIM.
At 6 months, PIM group had non-significantly higher validated abstinence than RIM group (10.
2% vs.
8.
3%, risk ratio [RR] 1.
23, 95%CI 0.
80 to 1.
88) at doubled cost (US$33,228.
8 vs.
15,985.
5).
In non-responders, receiving CCI (vs.
maintained PIM: 4.
8% vs.
6.
2%, RR 0.
77, 95%CI 0.
30 to 1.
97) or PIM (vs.
maintained RIM: 3.
3% vs 5.
7%, RR 0.
58, 95%CI 0.
17 to 1.
95) did not increase validated abstinence.
The PIM-based adaptive intervention did not significantly increase validated abstinence than that of non-personalized IM.
Non-responders to PIM or RIM did not benefit from more intensive interventions.
ClinicalTrials.
gov Identifier: NCT03992742.
Related Results
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Comparison of mHealth and Face-to-Face Interventions for Smoking Cessation Among People Living With HIV: Meta-Analysis (Preprint)
Comparison of mHealth and Face-to-Face Interventions for Smoking Cessation Among People Living With HIV: Meta-Analysis (Preprint)
BACKGROUND
The prevalence of smoking among people living with HIV (PLHIV) is higher than that reported in the general population, and it is a significant ri...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Problem-Based mHealth Literacy Scale (PB-mHLS): Development and Validation
Problem-Based mHealth Literacy Scale (PB-mHLS): Development and Validation
Background
Mobile devices have greatly facilitated the use of digital health resources, particularly during the COVID-19 pandemic. Mobile health (mHealth) has b...
Varenicline Versus Cytisine for Smoking Cessation in a Primary Care Setting: A Randomized Controlled Trial
Varenicline Versus Cytisine for Smoking Cessation in a Primary Care Setting: A Randomized Controlled Trial
Abstract
Our study aims to implement a smoking cessation program using pharmacotherapy in a real-life setting — primary care practices in Croatia and Slovenia — and...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...

